Immtech Home page Immtech company Immtech Business Development Immtech contact Immtech Technology Immtech R&D pipeline
Immtech Investor Information Immtech investor news releases Immtech SEC Filings Immtech Corporate Governance Immtech FAQs  

Business Model

We target cures for diseases
that globally
affect millions
of people, and
for which there
are significant unmet needs.

Immtech has a cost-effective drug development paradigm in the
pharmaceutical industry.

Targeting Diseases in Need of New Treatments
We aim to develop cures for infectious diseases that affect the global community
and for which there are significant unmet needs. Although the infectious disease
market represents an estimated US$46 billion in annual sales, relatively few new
drugs have been developed to treat infectious diseases during the last twenty years.

Accelerating the Pace, and Reducing the Cost, of Commercialization
Immtech focuses on moving compounds from discovery to commercialization at a fraction
of the cost of similar development efforts at large pharmaceutical companies. We
accomplish this by using our Scientific Consortium, a group of scientists who perform
early-stage discovery research. By tapping into the expertise of these university-based
researchers, Immtech aims to identify promising research platforms and develop drug
candidates efficiently.

Innovative Funding Strategies           
In addition to fundraising in the equity markets, we have funded part of our discovery
costs with non-dilutive sources that include grants from the National Institutes of
Health (NIH) and other foundations. Through members of the Immtech Scientific Consortium,
led by the University of North Carolina at Chapel Hill, we have also received funding from
the Bill and Melinda Gates Foundation.


Terms of Use | Privacy Policy
© 2008 Immtech. All Rights Reserved